Abstract：
Targeting genes using siRNA shows promise as an approach to alleviate symptoms of diabetic neuropathy. It focuses on neuropathies and distal symmetric polyneuropathy (DSPN) to explore the potential use of small interfering RNA (siRNA) as a treatment for diabetic neuropathy. Timely identification and management of neuropathy play a critical role in mitigating potential complications. RNAi success depends on understanding factors affecting small interfering RNA (siRNA) functionality and specificity. These include sequence space restrictions, structural and sequence features, mechanisms for nonspecific gene modulation, and chemical modifications. Addressing these factors enhances siRNA performance for efficient gene silencing and confidence in RNAi-mediated genomic studies. Diabetic retinopathy, particularly in South Asian, African, Latin American, and indigenous populations, is a significant concern due to its association with diabetes. Ethnicity plays a crucial role in its development and progression. Despite declining rates in the US, global trends remain concerning, and further research is needed to understand regional differences and reinforce ethnicity-based screening and treatment protocols. In this regard, siRNA emerges as a valuable instrument for early intervention strategies. While presenting promising therapeutic applications, siRNA utilization encounters challenges within insect pest control contexts, thereby providing insights into enhancing its delivery mechanisms for neuropathy treatment purposes. Recent advancements in delivery modalities, such as nanoparticles, allow for the controlled release of siRNA. More investigation is necessary to grasp the safety and efficacy of siRNA technology fully. It holds promise in transforming the treatment of diabetic neuropathy by honing in on particular genes and tackling issues such as inflammation and oxidative stress. Continuous advancements in delivery techniques have the potential to enhance patient results significantly. SiRNA targets genes in diabetic neuropathy, curbing nerve damage and pain and potentially preventing or delaying the condition. Customized treatments based on genetic variations hold promise for symptom management and enhancing quality of life.
摘要：
使用siRNA靶向基因显示出有望作为缓解糖尿病性神经病变症状的方法。它专注于神经病和远端对称性多发性神经病（DSPN），以探索小干扰RNA（siRNA）作为糖尿病性神经病的治疗的潜在用途。及时识别和治疗神经病变在减轻潜在的并发症中起着至关重要的作用。RNAi的成功取决于理解影响小干扰RNA(siRNA)功能性和特异性的因素。这些包括序列空间限制，结构和序列特征，非特异性基因调节的机制，和化学修饰。解决这些因素增强了siRNA在RNAi介导的基因组研究中的有效基因沉默和信心的性能。糖尿病视网膜病变，特别是在南亚，非洲,拉丁美洲,和土著居民，是一个重要的问题，因为它与糖尿病有关。种族在其发展和进步中起着至关重要的作用。尽管美国的利率下降，全球趋势仍然令人担忧，需要进一步的研究来了解地区差异并加强基于种族的筛查和治疗方案。在这方面,siRNA成为早期干预策略的有价值的工具。在提出有希望的治疗应用的同时，siRNA的利用在昆虫害虫控制环境中遇到挑战，从而为神经病治疗目的提供增强其递送机制的见解。交付方式的最新进展，比如纳米粒子，允许控制释放的siRNA。要充分掌握siRNA技术的安全性和有效性，还需要更多的研究。通过磨练特定基因并解决炎症和氧化应激等问题，它有望改变糖尿病神经病变的治疗方法。递送技术的不断进步具有显著提高患者结果的潜力。SiRNA靶向糖尿病神经病变的基因，抑制神经损伤和疼痛，并有可能预防或延迟病情。基于遗传变异的定制治疗有望为症状管理和提高生活质量提供希望。
